Resume

EDUCATION

  • August 1999 – June 2005.
    PhD from Roswell Park Graduate Division of SUNY, Buffalo, in Molecular and Cellular Biophysics program under Department of Cancer Biology with interaction with Dept of Pharmacology & Therapeutics. Awarded full scholarship and fellowship by Roswell Park Cancer Institute. Title of thesis: NON-INVASIVE IN VIVO ASSESSMENT OF TUMOR HYPOXIA USING FUNCTIONAL MAGNETIC RESONANCE (fMR) IMAGING DURING THERAPY IN HUMAN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) XENOGRAFTS: IMPLICATIONS FOR ASSESSING THERAPEUTIC EFFICACY.

  • October 2002.
    Completion of three years study in classical homeopathy with scholarship from the International Academy of Classical Homeopathy, New York. This is a homeopathy course under George Vithoulkas – the winner of 1996 Right Livelihood award (alternate noble prize) for his contribution to the revival of classical homeopathy.

  • December 1997
    Masters degree in Psychology (MA) from Annamalai University, India.

  • March 1997
    Postgraduate diploma in Guidance and Counseling (PGDGC) from Annamalai University, India

  • Dec 1996
    Diploma in Homeopathic Pharmacy (DHPh) from British Institute of Homeopathy, UK.

  • August 1994
    Completion of Doctorate of Homeopathic Medicine (HMD) from British institute of Homeopathy, UK.

  • May 1994
    Completion of Proficiency certificate in Acupuncture from Chinese Academy of Science.

  • March 1992
    Diploma in Acupuncture from Open International University of Complementary Medicine, Sri Lanka.

  • October 1992
    Diploma in homoepathy  (DIHom) from British Institute of Homeopathy, UK.

  • 1985
    MS in Biophysics from Cancer Research Institute under University of Bombay

  • 1983
    BS in Microbiology from University of Bombay.

Other Education

  • December 1988
    Diploma in Management Studies (DMS) from University of Bombay, India.

  • March 1993
    Baccalaureate in law (LLB) from University of Bombay.

  • January 1991
    Diploma in Export Import Management from Indian Merchants Chambers, Bombay, India.

Career in Health Sciences

  • June 17th 2022 – Ongoing
    In view of the possibility of NIH furthering clinical trial for Prolidase as an anti-cancer agent in the near future, and, in view of the potential impact it can have on cancer patients ; I have continued being part of the ongoing research efforts to further the translation to the clinic as a Part time Research Scientist in the Office of Clinical Transformation, Department of Pharmacology and Toxicology, Goodwin Research Lab., VCU Massey Cancer Center, Richmond, VA. I am thankful and indebted to my patients for their encouragement and support and understanding.
  • April 17th 2019 – April 2022 
    In view of the important research being pursued with clinical impact, was asked to rejoin and commit to the continued effort and did so on part time basis as a Research Associate w.e.f April 17th 2019 till April 2022 when the group moved to VCU Health – Massey Cancer Center, RIchmond, VA.

  • December 2015 – September 28 2018
    Advisor and Steering Committee Member for Wellness and Integrative Medicine Center at Roswell Park Cancer Institute, Buffalo, NY, USA.

  • October 27 2016 – September 28 2018
    Retired as an Affiliate Member in the Department of Pharmacology & Therapeutics (2016 – 2018), Roswell Park Comprehensice Cancer Center, Buffalo, NY. Research involved investigating novel anticancer properties of Prolidase in preclinical cancer models including breast, colorectal and bladder cancer.

  • June 2008 – September 2014
    Associate Research Professor, Department of Natural Sciences, Roswell Park Graduate Division, State University of New York at Buffalo.
  • January 15 2009 – October 26 2016
    Affiliate Member in the Department of Cancer Prevention and Control (2009 – 2016), Roswell Park Cancer Institute, Buffalo, NY. Research involved investigating anticancer properties of natural products such as broccoli, horse radish, wasabi, mustard and selenium in preclinical cancer models including head & neck, lung, colorectal and bladder cancer.
  • September 19, 2005 – January 14 2009
    Postdoctoral training in Translational Pharmacology and Physiology under tutelage of Dr Youcef M Rustum, Distinguished Professor and Chair, Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY. Research involved understanding effect of organoselenium compounds on tumor microenvironment including neoangiogenesis, tumor vessel maturation using various non invasive MR and optical techniques to assess the tumor microenvironment over time and treatment. In vivo xenografts of human lung, colorectal and head/neck cancer models are used along with in vitro tube formation assays for studying angiogenesis. Postdoctoral Fellow from Jan-May 2009 in Department of Cancer Chemoprevention
  • September 2, 2004 till August 31 2004
    Research Technologist, Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • April 2002 onwards

    1. Homeopathy teacher, educator, tutor, mentor and seminar speaker in North America.

    2. Homeopathic Tutor for British Institute of Homoepathy, Canada and USA.

    3. Since October 2004, adjunct faculty with Akamai University for homeopathic education.

    4. Homeopath practitioner in North America including Hom (ON) and RSHom(NA)

  • July 1992 till august 1999
    Director, coordinator – Centre for Homeopathic Cure, India. Responsibilities included overseeing activities of homeopathic medical doctors at the Centre, teaching intern homeopathic medical doctors, organizing seminars, homeopathic practice, managing finances coordinating different staff and functions.

  • April 1996 till March 1997
    Managing Editor – Health Newsletter, India.

Careers – Other

  • July 1989 till August 1999
    Director – Alpha Trade Links, India. Consultants to Himedia Laboratories P Ltd., Ceekay Daikin Ltd. and other corporations on international trade related matters.

  • June1996 till March 1999
    Faculty member – Institute of Management and Professional Studies, Mulund, Bombay, India. Taught International marketing to graduate students.

  • January 1999 till March 1999
    Visiting Faculty – Melange Institute of Management, India. Taught International marketing to graduate students.

  • May 1988 till July 1989
    Manager – Exports & Imports. Intec Polymers Ltd., Bombay, India

  • May 1987 till May 1988
    Purchase Executive, Intec Polymers Ltd., Bombay, India

  • June 1985 till September 1986
    Project Executive, Thomas Baker Pvt. Ltd., Bombay, India.

[/toggle_framed]

[toggle_framed title=”Grants and Awards”]

  1. National Institute of Health 2 year R21 award effective May 1st 2009 (CA133682-01A2) ‘Dietary Supplement Selenium and HIF-1 alpha Regulation in Cancer’.

  2. American Institute for Cancer Research postdoctoral grant for 2 years effective July 1st. 2006

  3. American Association for Cancer Research instituted AACR-AFLAC Scholar-in-Training Award for 2006;

  4. International Society for Magnetic Resonance in Medicine Award for annual meeting, 2006;

  5. Scholarship from Roswell Park Cancer Institute to attend 7th. International Summer School of Biophysics, Croatia, 2000;

  6. Fellowship with scholarship at Roswell Park Cancer Institute & SUNY, Buffalo, NY for PhD studies;

Patent

  1. #20080019919 – Method for optimizing cancer therapy by monitoring maturation of tumor associated vasculature by selenium.
  2. #61/313,004 – Novel method for delivery and use of isothiocyantes and its conjugates against bladder cancer growth and metastasis.
  3. #13/609,53 (US), #201180013514.5 (China), #11754150.8 (EP) and #7668/DELNP/2012 – Novel method for delivery and use of isothiocyanates for prophylaxis and/or therapy of bladder cancer.
  4. #62/039,497 & PCT/US15/46000 – Method for prophylaxis and/or treatment of ErbB1 positive cancers.
  5. #62/186,439 & PCT/US16/40423 – Diagnostic test for Alzheimer’s disease based on identification of a proteolytic pathway.

OTHER AWARDS AND RECOGNITIONS

  1. Doctorate of Science (DSc) – Honoris-Causa by Open International University of Complementary Medicine for services in homeopathy;

  2. Recipient of College Merit Scholarship twice at Baccalaureate level;

  3. Fellow of the International Laser therapy Association;

  4. Fellow of the British Institute of Homeopathy;

  5. Fellow member of United Writers’ Association, India;

  6. Fellow of the Homeopathic Foundation, Sri Lanka;

  7. Fellow of the Acupuncture Foundation of Sri Lanka;

  8. SUNY at Buffalo Graduate Student Association Distinguished Service Recognitions as a Finance Commissioner for 2001-2.

[/toggle_framed]

[toggle_framed title=”Memberships”]

  1. Registered full member with College of Homeopaths of Ontario;
  2. RSHom (NA) – North American Society of Hoomeopaths;
  3. American Association for Cancer Research (AACR) till 2013;
  4. International Society For Magnetic Resonance in Medicine (ISMRM) till 2013;
  5. American Association of Physicists in Medicine (AAPM) till 2013;
  6. Homeopathic Medical Council of Canada (HMCC);
  7. National United Professional Association of Trained Homeopaths (NUPATH), Canada;
  8. Associate member of the Institute of Company Secretary of India;
  9. International German Homoeopathic Society;
  10. Commonwealth Institute of Acupuncture & Natural Medicine;
  11. Member of the Acupuncture Foundation of SriLanka;
  12. Ex-member of Bombay Management Association;
  13. Ex-associate member of the International Federation of Practitioners of Natural Therapeutics, UK.

[/toggle_framed]

[toggle_framed title=”Publications”]

  • Lu Y, Bhattacharya A, Peterson D, Li Y,  Liu X, Marangoni E, Robila V, Zhang Y. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models. Drug Resistance Updates. Accepted, Mar, 2024.
  • Lu Y, Bhattacharya A, Li Y,  Sexton S, Ling X, Li F, Zhang Y. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2022, Published 2nd Jun 2022. https://doi.org/10.1186/s13046-022-02389-z
  • Lu Y, Li Y, Bhattacharya A, Zhang Y. Loss of peptidase D binding restores the tumor suppressor functions of oncogenic p53 mutants. Nature Communications Biology, 2021, 4:1373 published 8th December 2021. https://doi.org/10.1038/s42003-021-02880-x
  • Lu Y, Li Y, Bhattacharya A, Zhang Y. A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer. Science Translational Medicine, 23 Jan 2019: Vol. 11, Issue 476, eaav1620. DOI: 10.1126/scitranslmed.aav1620
  • Rustum YM, Chintala, Durrani FA, Bhattacharya A. Non-coding micro RNAs and hypoxia-inducible factors are selenium targets for development of a mechanism based combination strategy in clear cell renal cell carcinoma – bench to bedside therapy. Int. J. Mol. Sci. 2018, 19, 3378; doi:10.3390/ijms19113378
  • Li Y, Chen Z, Paonessa J D, Bhattacharya A, Glatt H, Vouros P, Zhang Y. Strong impact of sulfotransferases on DNA adduct formation by 4-aminobiphenyl in bladder and liver in mice. Cancer Medicine, 2018. DOI:10.1002/cam4.1779.
  • Lu Y, Li Y, Bhattacharya A, Zhang Y. PEPD is an essential regulator of p53 tumor suppressor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78 (13 Suppl):Abstract nr 552.
  • Zakharia Y, Bhattacharya A, Rustum Y M. Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development. Oncotarget, 9, 10765-10783, 2018. . Doi.org/10.18632/oncotarget.24297
  • Yang Lu, Li Y, Bhattacharya A, Zhang Y. PEPD is a pivotal regulator of p53 tumor suppressor. Nature Communications, 8(2052), 2017. DOI: 10.1038/s41467-017-02097-9
  • Yang Lu, Li Y, Bhattacharya A, Zhang Y. Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D. Oncotarget, 2016. DOI:10.18632/oncotarget.9851.
  • Yang L, Bhattacharya A, Zhang Y. A plasma proteolysis pathway comprising blood coagulation proteases. Oncotarget, 2016 Feb 7, doi: 10.18632/oncotarget.7261, 2016
  • Bhattacharya A, Zhang Y. Editorial: Role of homeopathy in integrative cancer care. Carcinogenesis and Mutagenesis, 6, 2016. DOI: 10.4172/2157-2518.1000e118.
  • Yang L, Li Y, Bhattacharya A, Zhang Y. Inhibition of ERBB2-overexpressing tumors by recombinant human Prolidase and its enzymatically inactive mutant. EBioMedicine, 2,396-405, 2015. http://dx.doi.org/10.1016/j.ebiom.2015.03.016.
  • Veeranki O L, Bhattacharya A, Tang L, Marshall J R, Zhang Y. Cruciferous vegetables, isothiocyanates, and prevention of bladder cancer. Curr Pharmacol Rep., DOI 10.1007/s40495-015-0024-z, 2015.
  • Bhattacharya A, Klaene J J, Li Y, Paonessa J, Stablewski A B, Vouros P, Zhang Y. The inverse relationship between bladder and liver in 4-aminobiphenyl-induced DNA damage. Oncotarget, 6(2), 836-845, 2014.
  • Bhattacharya A, Li Y, Shi Y, Zhang Y. Enhanced inhibition of urinary cancer growth and muscle invasion by allyl iothiocyanate and celecoxib in combination. Carcinogenesis.Carcinogenesis, 34(11), 2593-2599, 2013.
  • Veeranki O L, Bhattacharya A, Marshall J R, Zhang Y. Organ-Specific Exposure and Response to Sulforaphane, a Key Chemopreventive Ingredient in Broccoli: Implications for Cancer Prevention. British Journal of Nutrition, 109, 25-32, 2012.
  • Book Chapter: Bhattacharya A. ‘Towards a better understanding of health and disease’ in ‘A compendium of Essays on Alternative Therapy’. ISBN 978-953-307-863-2. Intech-Open Access Publishers, Rijeka, Croatia. 2012.
  • Bhattacharya A, Li Y, Geng F, Munday R, Fahey J W, Zhang Y. The principal urinary metabolite of allyl isothiocyanate, N-acetyl-S-(N-allylthiocarbamoyl)cysteine, inhibits the growth and muscle invasion of bladder cancer. Carcinogenesis, 33(2), 394-398, 2012.
  • Azrak R.G, Cao S, Durrani F A, Tóth K, Bhattacharya A, Rustum Y M. Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation. Cancer Letters, 311(2), 219-229, 2011, doi:10.1016/j.canlet.2011.07.023.
    Link to Article
  • Bhattacharya A. Methylselenocysteine – a Promising Antiangiogenic Agent for Overcoming Drug Delivery Barriers in Solid Malignancies for Therapeutic Synergy with Anticancer Drugs. Expert Opinion on Drug Delivery, 8(6), 749-763, 2011.
  • Bhattacharya A, Turowski S G, San Martin I D, Rajput A, Rustum Y M, Hoffman R M, Seshadri M. Magnetic resonance and fluorescence-protein imaging of anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer. Anticancer Research, 31, 387-394, 2011.
  • Bhattacharya A, Turowski S G, San Martin I D, Rajput A, Rustum Y M, Hoffman R M, Seshadri M. Combined magnetic resonance and fluorescence-protein imaging to simultaneously assess the antitumor and anti-antiangiogenesis efficacy of selenium. Proc. Am. Assoc. Cancer Res. (Abstract#4284), 2011.
  • Bhattacharya A, Li Y, Wade K L, Paonessa J D, Fahey J W, Zhang Y. Allyl isothiocyanate-rich mustard seed powder inhibits bladder cancer growth and muscle invasion. Carcinogenesis, 31(12), 2105-2110, 2010; doi: 10.1093/carcin/bgq202.
    Link to Article
  • Chintala s, Tóth K, Yin M-B, Bhattacharya A, Smith S B, Ola M S, Cao S, Durrani F A, Zinia T R, Dean R, Slocum H K, Rustum Y M. Downregulation of cystine transporter Xc¯ by irinotecan in human head and neck cancer FaDu xenografts. Chemotherapy. Chemotherapy, 56(3), 223-233, 2010.
  • Rustum Y M, Tóth K, Seshadri M, Sen A, Durrani FA, Stott E, Morrison C D, Cao S, Bhattacharya A. Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound. Journal on Oncology, Article ID 396286. doi:10.1155/2010/396286.
    Link to Article
  • Bhattacharya A, Tang L, Li Y, Geng F, Paonessa J, Chen S C, Wong M, Zhang Y. Inhibition of bladder cancer by allyl isothiocyanate. Carcinogenesis, 31(2), 281-286, 2010; doi: 10.1093/carcin/bgp303.
    Link to Article
  • Bhattacharya A, Tang L, Li Y, Geng F, Paonessa J, Chen S C, Wong M, Zhang Y. Bladder cancer inhibition by allyl isothiocyanate. Proc. Am. Assoc. Cancer Res., Frontiers in Cancer prevention Research, 2009.
  • Bhattacharya A, Tóth K, Sen A, Seshadri M, Cao S, Durrani FA, Faber E, Repasky E, Rustum Y M. Inhibition of colon cancer growth by methylselenocysteine – induced angiogenic chemomodulation is influenced by histological characteristics of the tumor. Clinical Colorectal Cancer 8(3), 155-162, 2009.  Link to Article
  • Bhattacharya A. A model of health and disease in homeopathy. The American Homeopath 14, 138-142, 2008.
  • Bhattacharya A, Tóth K, Durrani FA, Cao S, Slocum HK, Chintala S, Rustum Y M. Hypoxia Specific Drug Tirapazamine Does Not Abrogate Hypoxic Tumor Cells in Combination Therapy with Irinotecan and Methylselenocysteine in Well-Differentiated Human Head and Neck Squamous Cell Carcinoma A253 Xenografts. Neoplasia 10 (8), 857-865, 2008.  Link to Article
  • Bhattacharya A, Seshadri M, Oven S D, Tóth K, Vaughan M, Rustum Y.M. Tumor vascular maturation and improved drug delivery by organoselenium compound methylselenocysteine. Clinical Cancer Research 14(12), 3926-3932, 2008.  Link to Article
  • Cao S, Durrani FA, Bhattacharya A, Yu Y, Rustum YM. Enhanced irinotecan toxicity in UDPGT deficient rats: Role of UDPGT1A in irinotecan detoxification. Proc. Am. Assoc. Cancer Res., 2008.
  • Bhattacharya A, Tóth K, Cao S, Azrak R. G, Durrani F A, Rustum Y M. 5-Methylselenocysteine (MSC) causes tumor vessel maturation leading to synergistic antitumor effect in human xenografts. Proc. Am. Institute for Cancer Res., 2007.
  • Seshadri M, Bhattacharya A, Tóth K, Rustum Y M. Contrast-enhanced MRI of the vascular response of human tumor xenografts to the chemopreventive agent selenium in vivo: Implications for combination therapy. Proc. Am. Assoc. Cancer Res., 2007.
  • Bhattacharya A, Tóth K, Cao S, Azrak R. G, Durrani F A, Rustum Y M. Se-(Methyl)selenocysteine causes tumor vessel maturation leading to synergistic antitumor effect in human xenografts. The Journal of Nutrition, 137(1S), 278S, 2007.
  • Seshadri M, Mazurchuk R, Spernyak J A, Bhattacharya A, Rustum Y M, Bellnier D A. Activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) against human head and neck carcinoma xenografts. Neoplasia, 8(7), 534-542, 2006.  Link to Article
  • Bhattacharya A, Mazurchuk R, Spernyak J. A, Tóth K, Magnano, C.R, Cao S, Azrak R. G, Durrani F A, Rustum Y M. Tumor vessel maturation by 5-Methylselenocysteine (MSC) results in synergistic antitumor effect in human head and neck squamous cell carcinoma (HNSCC) xenografts. Proc. Am. Assoc. Cancer Res., 2006.
  • Bhattacharya A, Mazurchuk R, Spernyak J. A, Cao S, Durrani F A, Rustum Y M. Serial spin echo based BOLD fMR imaging can predict chemotherapy response in head and neck squamous cell carcinoma (HNSCC) xenografts. Proc. International Society of Magnetic Resonance in Medicine, 2006.
  • Seshadri M, Mazurchuk R, Spernyak J. A, Bhattacharya A, Rustum Y M, Bellnier, D.A. Tumor response of human head and neck squamous cell carcinoma (HNSCC) xenografts to the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Proc. Am. Assoc. Cancer Res., 2006
  • Cao S, Bhattacharya A, Durrani F A, Fakih M. Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer (Review Article). Expert opinion on pharmacotherapy, 7, 687-703, 2006.  Link to Article
  • Yin M-B, Li Z-R, Tóth K, Cao S, Durrani F A, Hapke G, Bhattacharya A, Azrak R G, Frank C, Rustum Y M. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase and hypoxia-inducible factor 1α expression, resulting in reduced angiogenesis.  Link to Article  Oncogene, 25, 2509-2519, 2006.
  • Bhattacharya A, Tóth K, Mazurchuk R, Spernyak J A, Slocum H K,  Pendyala L, Azrak R, Cao S, Durrani F A, Rustum Y M,: Lack of microvessels in well differentiated regions of head and neck squamous cell carcinoma (HNSCC) A253 is associated with fMR imaging detectable hypoxia, limited drug delivery and resistance to irinotecan therapy. Clinical Cancer Res, 10, 8005 – 8017, 2004.  Link to Article
  • Bhattacharya A, Tóth K, Azrak R, Pendyala L, Spernyak J, Cao S, Durrani F A, Mazurchuk R, Slocum H K, Rustum Y M. Resistance to irinotecan is associated with lack of microvessels, hypoxia and limited drug delivery in the well differentiated parts of human head and neck squamous cell carcinoma (HNSCC) A253. Proc. Am. Assoc. Cancer Res. 45, 2004.
  • Cao S, Durrani F A, Moser M T, Bhattacharya A, Foster B A, Rustum Y M. Se-(Methyl)Selenocysteine (MSC) potentiates the antitumor activity of Taxotere against Prostate Cancer inTramp model. Proc. Am. Assoc. Cancer Res, 45, 2004.
  • Bhattacharya A, Azrak R, Toth K, Cao S, Durrani F, Pendyala L, Mazurchuk R, Rustum Y M – Tumor hypoxia and differentiation status are markers associated with response to irinotecan (FU therapy) of xenografts bearing squamous cell carcinoma of the head and neck (SCCHN) tumors. Proc. Am. Assoc. Cancer Res. 44, 2003.
  • Bhattacharya A – The enigma of coffee restriction in homeopathic treatment. Asian Homeopathic Journal, 6(4), 33-36, 1996.
  • Bhattacharya A – Dietary effect on criminal behaviour.  Health Newsletter, 15, 4, 1996.
  • Bhattacharya A – A new model of health and diseases. Health Newsletter, 1996.
  • Bhattacharya A – Alleviating Anxiety neuroses nutritionally. Health Newsletter, 1996.
  • Bhattacharya A – Garlic – the health Panacea. Health Newsletter, 1996.
  • Bhattacharya A – Understanding minerals. Health Newsletter. 1996 & 1997.
  • BOOK EDITOR
    ‘A compendium of Essays on Alternative Therapy’. ISBN 978-953-307-863-2. Intech-Open Access Publishers, Rijeka, Croatia. 2012.

[/toggle_framed]

[toggle_framed title=”Mentoring”]

M.S – Thesis Committee and advisor for Steven Oven (‘Tumor vascular maturation by Se-(Methyl)-Selenocysteine in human head and neck squamous cell carcinoma (HNSCC) xenografts’, March 2007).

Since November 2019 – Examiner for mini-dissertation for Master Degree Homoeopathy students at the Durban University of Technology
Summer Students – Mentor for Summer Students Science Program for high school and college students at Roswell Park Cancer Institute, Buffalo, NY
Homeopathy – Mentor for students and practitioners at various levels of education and training
Instructor ‘Introduction to Holistic Health and Homeopathy’ module, Fall 2019 at The Best Center, SUNY at Genesio Community College, Batavia, NY.

[/toggle_framed]

[toggle_framed title=”Symposia – Invited Speaker/Reviewer”]
[fancy_table]

1/4-1/5/2005 Buffalo, NY

Invited speaker at Selenium Workshop

Title:  “Angiogenic activity of selenium: Comparative studies with standard agent”
2/14-2/16/2006 Seattle, Washington

Oral presentation – Oral Scientific Session at 14th. ISMRM Scientific meeting.

Title:  “Assessment of spin echo BOLD fMR imaging as a prognostic tool for determining chemotherapeutic efficacy ”
12/30/2007 Toronto, ON

Invited Speaker – Homeopathic Medical Council of Canada

Title:  “Cancer and Autoimmune Diseases – A Homeopathic Perspective ”
11/09/2008 Toronto, ON

Invited Keynote Speaker – The National United Professional Association of Trained Homeopaths (NUPATH) Annual Conference

Title:  “Homeopathic Detoxification – Freeing the Complex Biological System for Creative Fulfillment.”
11/30/2009 Buffalo, NY

Invited Speaker – Gilda’s Club WNY. Ask the expert lecture

Title:  “Cancer and Homeopathy ”
10/29/2011 Daemen College, Amherst, NY

Organizer & Part Speaker – co-sponsored by Daemen College and Himalayan Institute, Buffalo.

Title:  “Is Homeopathy Effective Against Cancer? The Use of Banerji Protocol in Treatment of Cancer ” Drs Prasanta & Pratip Banerji and Arup Bhattacharya.
10/12- 10/14/2012 Toronto, Canada.

Invited Speaker – Canadian Homeopathic Conference.

Title: “The Magic of Nosodes – Microdoses Mega Results”
10/25/2012 Buffalo, NY

Invited Speaker – Fisher-Price

Title: “Introduction to Homeopathy”
10/23-24/2013 Daemen College, Amherst, NY.

Organizer of a 2 day systems and Symbiosis workshop on

Title: “Harnessing the Power of Bowel Nosodes”.  Dr. Russell Malcolm, Dean, Faculty of Homeopathy, UK.
03/06/2015 WHN webinar.

Title: “The Role of Classical homeopathy vs. Homeopathy Protocol Regimen in Modern Day Clinical Practice”.
10/02-03/2015 Buffalo & Erie County Library, Buffalo, NY

Seminar Organizer

Title:  “Treatment of advance pathology using homeopathy – underlying principles and concepts”. Dr. Farokh Master.
01/15-16/2016 Sarasota, FL.
FSOMA sponsored seminar at East West College, Sarasota, FL
Title: “Harnessing the information patterns in Homeopathy”
02/05-07/2016 Toronto, Canada.
Invited Speaker – Canadian Homeopathic Conference. Rogers Prize Excellence in Complementary and Alternative Medicine talk.
Title: “Cancer in Integrative Medicine from a Homeopath’s Perspective”.
05/14-15/2016 BeHealthy Institute, Hamburg, NY.
Seminar organizer
Title: “Homeopathic Treatment of Mental and Emotional Problems”. Kim Elia
11/05-06/2017 BeHealthy Institute, Hamburg, NY.
Seminar organizer
Title: “Metabolic and Auto-Immune Disorders”. Dr. Farokh Master
03/18-19/ 2017 BeHealthy Institute, Hamburg, NY.
Seminar organizer
Title: “The Elements: Exploring Jan Scholten’s Periodic System”. Sally Williams
05/20-21/2017 BeHealthy Institute, Hamburg, NY.
Seminar
Title: “Homeopathy for Treatment of Cancer”
06/20/21 Invited speaker – 7th International Webinar hosted by Forum for Invention & Services in Homeopathy (FISH), Odisha
Title: “Role of Genus Epidimicus in Homeopathy during the wave of COVID-19”

[/fancy_table]

  • Invited speaker to Joint Annual Conference in Homeopathy (JACH, Organized by National Center for Homeopathy, USA) – 2022 (‘Alleviating Dis-ease Through Emotional Destressing Using Homeopathy’);  2024 (‘Homeopathy in rescue role from autoimmune disease in the 21st century’).
  • Invited speaker to Canadian Homeopathic Conference, 2022 (‘Role of Integrative Homeopathy – Balancing the Inner Environment Through Optimal Vital Force Attenuation’).
  1. ISMRM – ESMRM 2007 joint annual meeting scientific abstract reviewer;
  2. Reviewer for scientific journal such as Molecular Cancer Therapeutics, Clinical Cancer Research, Cancer Research, Bioorganic & Medicinal Chemistry Letters, Expert Opinion on Emerging Drugs, and, Cancer Epidemiology, Biomarkers & Prevention.
  3. Canadian Institute of Health Research – External reviewer since 2008.
  4. Featured in ‘Scientist in spotlight’, Fall 2009, American Institute for Cancer Research, AICR ScienceNow, Volume 30, Fall 2009. http://www.aicr.org/site/News2?page=NewsArticle&id=17287&news_iv_ctrl=0&abbr=res_
  5. Invited by New York Academy of Sciences to participate in roundtable discussion on critical R&D global challenges for their PepsiCo Company Day on December 10, 2009.
  6. Featured under ‘Practitioner Spotlight’ in Buffalo, NY Edition of Natural Awakening, February, 2016.

[/toggle_framed]